Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company based in New Haven, Connecticut, has announced a conference call and live audio webcast scheduled for March 17, 2026, at 4:30 p.m. ET. This event will detail the company’s financial results for the fourth quarter and the full year ended December 31, 2025. In addition to financial reporting, senior management will provide key business updates during the session, which can be accessed through the company's website.

Trevi Therapeutics is at the forefront of addressing significant unmet medical needs with its investigational therapy, Haduvio™ (oral nalbuphine ER). This treatment targets chronic cough associated with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Notably, Haduvio is the first investigational therapy to demonstrate a statistically significant reduction in cough frequency in clinical trials for both patients with chronic cough linked to IPF and those with RCC, marking a potential breakthrough in the management of these debilitating conditions.

Chronic cough considerably affects a substantial portion of patients with IPF and non-IPF ILD, with an estimated 100,000 U.S. patients suffering from uncontrolled coughing. Meanwhile, RCC impacts 2-3 million Americans, presenting a challenging situation as it persists beyond standard treatment for other conditions. Trevi's Haduvio works by interacting with kappa and mu opioid receptors, influencing the cough reflex both centrally and peripherally, presenting a new hope for those affected.

With no FDA-approved therapies currently available for these conditions, Trevi Therapeutics remains dedicated to advancing its innovative treatment options. For further details and updates, stakeholders can visit www.TreviTherapeutics.com or follow the company on social media platforms.

Trevi Therapeutics, Inc. (Nasdaq: TRVI) is on the verge of a significant milestone, as it prepares to report its fourth-quarter and year-end financial results for 2025 on March 17, 2026. Investors should closely monitor this event due to Trevi's focus on developing Haduvio™ (oral nalbuphine ER) for chronic cough related to idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC)—conditions with heightened unmet medical needs.

Haduvio presents a unique value proposition by being the first investigational therapy to demonstrate a statistically significant reduction in cough frequency in clinical trials. With around 150,000 IPF patients and 2-3 million RCC patients in the U.S., the company is tapping into a substantial market. The absence of FDA-approved therapies for these conditions could position Haduvio as a critical solution, making Trevi a potentially attractive investment opportunity if clinical and regulatory progress continues.

Investors should pay attention to not only Trevi's financial results but also any updates on Haduvio’s development and regulatory path. Given the company's focus on a high-need patient population, successful trials could likely translate into strong commercial prospects. Any positive updates regarding Haduvio's safety and efficacy, or even advancements towards regulatory approvals, could generate significant interest and upward momentum in TRVI's stock price.

Moreover, Trevi's approach, utilizing the dual mechanism of action (KAMA) through opioid receptors, showcases its innovation in treating a debilitating condition. As the chronic cough market remains largely underserved, Haduvio's success could lead to a potential restructuring in therapeutic approaches for this segment.

In conclusion, stakeholders should stay informed about the impending conference call, as strategic insights from management could illuminate Trevi's path forward, influencing investment decisions significantly in the near term.